Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

2017

Bone Therapeutics strengthens board of directors

  • Read more about Bone Therapeutics strengthens board of directors

Bone Therapeutics Notice of Half Year 2017 Results

  • Read more about Bone Therapeutics Notice of Half Year 2017 Results

Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer

  • Read more about Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer

Bone Therapeutics announces H1 results for 2017

  • Read more about Bone Therapeutics announces H1 results for 2017

The preliminary documents for the Extraordinary General Shareholder Meeting on 5 October 2017 have been made available

  • Read more about The preliminary documents for the Extraordinary General Shareholder Meeting on 5 October 2017 have been made available

Bone Therapeutics reports strong interim results from ALLOB Phase IIA spinal fusion study

  • Read more about Bone Therapeutics reports strong interim results from ALLOB Phase IIA spinal fusion study

Bone Therapeutics announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis

  • Read more about Bone Therapeutics announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis

Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB in Japan

  • Read more about Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB in Japan

The preliminary documents for the Extraordinary General Shareholder Meeting on 30 October 2017 have been made available

  • Read more about The preliminary documents for the Extraordinary General Shareholder Meeting on 30 October 2017 have been made available

Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017

  • Read more about Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to 2017
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions